Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9R3WT)

Drug Name

AVE 0991 Drug Info

Synonyms

AVE 0991; 304462-19-9; AVE-0991; AVE0991; UNII-68JR6NCI7I; 68JR6NCI7I; GTPL5579; SCHEMBL15045765; KS-00000LDU; DTXSID50184526; C29H32N4O5S2; MolPort-019-995-543; BCP11067; ZINC3927311; 3460AH; FD5038; AKOS027338221; CS-1752; HY-15778; AK340230; 4CA-0212; 2-Thiophenesulfonamide, N-((ethylamino)carbonyl)-3-(4-((5-formyl-4-methoxy-2-phenyl-1H-imidazol-1-yl)methyl)phenyl)-5-(2-methylpropyl)-; AB0087841; B1007; A820377

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 9851724
CAS Number: CAS 304462-19-9
TTD Drug ID: DM9R3WT

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Proto-oncogene Mas (MAS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Angiotensin-(1-7)	DM76GZ0	Sarcoma	2A60-2C35	Phase 3	[3]
DSC-127	DMM0HAE	Diabetic foot ulcer	BD54	Phase 3	[3]
AR234960	DMTN10D	Discovery agent	N.A.	Investigative	[4]
AR244555	DM68QY0	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene Mas (MAS)	TTOISYB	MAS_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5579).
2	Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension. 2004 Oct;44(4):490-6.
3	New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst. 2012 Dec;13(4):505-8.
4	Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection. Am J Physiol Heart Circ Physiol. 2012 Jan 1;302(1):H299-311.